NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHMA shares have increased by 22.2% and is now trading at $4.79.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chiasma.

Chiasma will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chiasma Inc (NASDAQ:CHMA) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.05.
View Chiasma's earnings history.

3 Wall Street analysts have issued 12-month price objectives for Chiasma's stock. Their forecasts range from $11.00 to $19.00. On average, they anticipate Chiasma's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 234.0% from the stock's current price.
View analysts' price targets for Chiasma.

News stories about CHMA stock have trended very positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chiasma earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Chiasma.

Chiasma saw a decline in short interest in July. As of July 31st, there was short interest totaling 1,830,000 shares, a decline of 15.7% from the July 15th total of 2,170,000 shares. Based on an average daily trading volume, of 752,200 shares, the short-interest ratio is presently 2.4 days. Currently, 4.6% of the company's shares are short sold.
View Chiasma's Short Interest.

Some companies that are related to Chiasma include Cara Therapeutics (CARA), ORIC Pharmaceuticals (ORIC), Omeros (OMER), Morphic (MORF), Vectura Group (VEGPF), Assembly Biosciences (ASMB), Nkarta (NKTX), Legend Biotech (AMTI), ImmunoGen (IMGN), Passage Bio (KROS), ZIOPHARM Oncology (ZIOP), Tricida (TCDA), Akouos (AKUS), Frequency Therapeutics (FREQ) and Eagle Pharmaceuticals (EGRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bessemer Group Inc. (0.13%), WINTON GROUP Ltd (0.13%), Virtu Financial LLC (0.09%), Trexquant Investment LP (0.07%), SG Americas Securities LLC (0.05%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and WINTON GROUP Ltd.
View insider buying and selling activity for Chiasma.

CHMA stock was bought by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtu Financial LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.79.

Chiasma has a market capitalization of $202.43 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]